FDA Approves New Arthritis Drug, Bextra

by Medindia Content Team on  December 5, 2001 at 3:13 PM Drug News
RSS Email Print This Page Comment
FDA Approves New Arthritis Drug, Bextra
The US Food and Drug Administration has approved a new drug for treating osteoarthritis. Osteoarthritis is a progressive deterioration in the cartilage of certain joints. Unlike rheumatoid arthritis, which is an inherited autoimmune disease, osteoarthritis results from overuse of joints, and can be a byproduct of strenuous sports, obesity or aging.
Advertisement

Pharmacia Corp. makes the drug, Bextra (valdecoxib), while drug giant Pfizer Inc. is helping to promote it. Bextra is a member of a class of anti-inflammatory drugs known as COX-2 inhibitors, which work by blocking an enzyme called cyclooxygenase 2.

Advertisement
These drugs are believed to sidestep the stomach-irritating effects of other nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin. The drug would also be indicated for treating rheumatoid arthritis and menstrual pain. The exact launch date and price per dose has yet to be determined.

Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Osteoarthritis Oligoarthritis Spondylolisthesis Signature Drug Toxicity Knee Replacement Reiterís syndrome Arthritis Septic Arthritis Physiotherapy for Arthritis 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive